Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471434 | 0.90 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL13920890 | 0.86 | MCHR1 (0.62) | MCHR1 | |
| SCHEMBL13920891 | 0.86 | MCHR1 (0.62) | MCHR1NPC1RAB9A | |
| SCHEMBL13920892 | 0.82 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL13920886 | 0.81 | MCHR1 (0.80) | MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL20374775 | 0.78 | MCHR1 (0.72) | MCHR1MAP3K5NPC1RAB9A | |
| SCHEMBL14701600 | 0.78 | MCHR1 (0.59) | MCHR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13920887 | 0.77 | SMN1; SMN2 (0.59) | MCHR1MAPT | |
| SCHEMBL26603203 | 0.77 | NPC1 (0.62) | MCHR1PTPN1MEN1NPC1MAPK1 | |
| SCHEMBL31683201 | 0.77 | KDM4E (0.53) | MCHR1PTPN1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | MCHR1 4/4885PTPN1 1255/4885MAP3K5 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.